SCHEMBL2945245

SCHEMBL2945245

c1ccc(Cn2cc(-c3ncc(-c4ccc5cc(OCc6nnn[nH]6)ccc5c4)o3)c3ccccc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.38
ENPP2 Q13822 2/20 0.37
CA12 O43570 3/20 0.36
CA9 Q16790 3/20 0.36
ESR1 P03372 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
F2RL3 Q96RI0 1/20 0.34
KDR P35968 2/20 0.34
EGFR P00533 2/20 0.33
MET P08581 2/20 0.33
KCNH2 Q12809 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949496 0.87 KDM4E (0.39) PTPN1
SCHEMBL2945759 0.83 SIRT2 (0.39) PTPN1ENPP2CA12CA9ESR1
SCHEMBL2946384 0.83 SIRT2 (0.44) ENPP2CA12CA9ESR1CA1
SCHEMBL2943810 0.82 THRA (0.44) PTPN1ENPP2CA12CA9CA1
SCHEMBL2944827 0.81 ENPP2 (0.48) PTPN1ENPP2CA12CA9ESR1
SCHEMBL2946099 0.81 TSHR (0.46) PTPN1KDR
SCHEMBL2945320 0.77 PPARG (0.46) PTPN1F2RL3
SCHEMBL2946398 0.77 FFAR1 (0.39) PTPN1CA12CA9CA1CA2
SCHEMBL2951909 0.75 F2RL3 (0.42) PTPN1ENPP2CA12CA9CA1
SCHEMBL2948596 0.73 MEN1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US claimed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP claimed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US claimed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO claimed
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US disclosed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP disclosed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US disclosed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052348-A1 Oxazolo-naphthyl acids SERPINE1, SERPINB1, SERPINC1 PTPN1 1585/4885ENPP2 135/4885CA12 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.